Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $29.16 USD
Change Today +0.02 / 0.07%
Volume 217.2K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 11:46 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Open
$29.28
Previous Close
$29.14
Day High
$29.86
Day Low
$28.81
52 Week High
01/13/15 - $45.45
52 Week Low
08/1/14 - $28.26
Market Cap
1.2B
Average Volume 10 Days
809.3K
EPS TTM
$0.64
Shares Outstanding
42.8M
EX-Date
--
P/E TM
45.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACORDA THERAPEUTICS INC (ACOR)

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinson’s disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.

489 Employees
Last Reported Date: 02/27/15
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $745.8K
Chief Financial Officer
Total Annual Compensation: $428.3K
Chief of Business Operations
Total Annual Compensation: $312.7K
President of International, General Counsel a...
Total Annual Compensation: $555.5K
Chief Medical Officer
Total Annual Compensation: $434.0K
Compensation as of Fiscal Year 2014.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM. Venue: Time Warner Center, New York, United States. Speakers: Jane Wasman, President of International, General Counsel and Corporate Secretary.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for 2015

Acorda Therapeutics, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2015. The company reported a GAAP net loss of $3.1 million for the quarter ended March 31, 2015, or $0.07 per diluted share. GAAP net income in the same quarter of 2014 was $0.7 million, or $0.02 per diluted share. Non-GAAP net income for the quarter ended March 31, 2015 was $6.5 million, or $0.15 per diluted share. Non-GAAP net income in the same quarter of 2014 was $8.8 million, or $0.21 per diluted share. For the quarter ended March 31, 2015, the company reported combined net revenue and royalties from ZANAFLEX and tizanidine of $2.6 million compared to $3.1 million for the same quarter in 2014. Total revenue was $99,851,000 compared to $80,518,000 a year ago. Operating loss was $1,259,000 compared to income of $3,416,000 a year ago. Loss before income taxes was $5,123,000 compared to income of $3,496,000 a year ago. The company is reiterating 2015 AMPYRA net sales guidance of $405-$420 million. The company is reiterating 2015 R&D guidance of $150-$160 million. The company is reiterating 2015 SG&A guidance of $180-$190 million. The company expects to be cash flow positive in 2015.

Acorda Therapeutics, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Acorda Therapeutics, Inc., Q1 2015 Earnings Call, Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $29.16 USD +0.02

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $36.59 USD +0.90
Biogen Inc $385.18 USD -0.62
Depomed Inc $23.65 USD +0.29
Durect Corp $2.27 USD -0.019
Isis Pharmaceuticals Inc $60.62 USD +2.28
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 94.4x
Price/Sales 3.1x
Price/Book 2.4x
Price/Cash Flow 95.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit www.acorda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.